Clinical evaluation of germline polymorphisms associated with capecitabine toxicity in breast cancer: TBCRC-015-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Clinical evaluation of germline polymorphisms associated with capecitabine toxicity in breast cancer: TBCRC-015

Published:2020-05-06 Issue:3 Volume:181 Page:623-633
ISSN:0167-6806
Container-title:Breast Cancer Research and Treatment
language:en
Short-container-title:Breast Cancer Res Treat

Author:

O’Donnell Peter H.^ORCID, ,Trubetskoy Vassily,Nurhussein-Patterson Ashley,Hall Julianne P.,Nath Aritro,Huo Dezheng,Fleming Gini F.,Ingle James N.,Abramson Vandana G.,Morrow P. K.,Storniolo Anna Maria,Forero Andres,Van Poznak Catherine,Liu Minetta C.,Chang Jenny C.,Merkel Douglas E.,Peppercorn Jeffrey M.,Rugo Hope S.,Dees E. Claire,Hahn Olwen M.,Hoffman Philip C.,Rosner Gary L.,Huang R. Stephanie,Ratain Mark J.,Cox Nancy,Olopade Olufunmilayo I.,Wolff Antonio C.,Dolan M. Eileen,Nanda Rita

Funder

Avon Foundation for Women

The Breast Cancer Research Foundation

Susan G. Komen for the Cure

National Cancer Institute

National Institute of General Medical Sciences

University of Chicago Cancer Research Center

Center for Clinical and Translational Science, University of Illinois at Chicago

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

https://link.springer.com/content/pdf/10.1007/s10549-020-05603-8.pdf

Reference50 articles.

1. Stockler MR et al (2011) Capecitabine versus classical cyclophosphamide, methotrexate, and fluorouracil as first-line chemotherapy for advanced breast cancer. J Clin Oncol 29(34):4498–4504

2. O'Shaughnessy J et al (2002) Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 20(12):2812–2823

3. Wang J et al (2015) Capecitabine combined with docetaxel versus vinorelbine followed by capecitabine maintenance medication for first-line treatment of patients with advanced breast cancer: Phase 3 randomized trial. Cancer 121(19):3412–3421

4. Masuda N et al (2017) Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N Engl J Med 376(22):2147–2159

5. Ratain MJ (2002) Dear doctor: we really are not sure what dose of capecitabine you should prescribe for your patient. J Clin Oncol 20(6):1434–1435

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Novel apaQTL-SNP for the Modification of Non-Small-Cell Lung Cancer Susceptibility across Histological Subtypes;Cancers;2022-10-28

2. Genophenotypic Factors and Pharmacogenomics in Adverse Drug Reactions;International Journal of Molecular Sciences;2021-12-10

3. A case-control study of a combination of single nucleotide polymorphisms and clinical parameters to predict clinically relevant toxicity associated with fluoropyrimidine and platinum-based chemotherapy in gastric cancer;BMC Cancer;2021-09-16

4. An Example of Personalized Treatment in HR+ HER2+ Long Survivor Breast Cancer Patient (Case Report);Current Oncology;2021-05-25

5. Capecitabine-Induced Terminal Ileitis: Case Report and Literature Review;Cureus;2021-04-21

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3